Pharmacyclics Inc

Pharmacyclics — Conference Presentation (December 2010)

20 slides from Pharmacyclics's conference presentation, Dec 6, 2010

  1. Slide 1: PCI-32765 Is Well Tolerated and Demonstrates Promising Clinical Activity in CLL and SLL

    THE BRUTON’S TYROSINE KINASE INHIBITOR, PCI-32765, Is WELL TOLERATED AND DEMONSTRATES PROMISING CLINICAL ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND SMALL LYMPHOCYTIC LYMPHOMA (SLL): AN UPDATE ON ONGOING PHASE 1 STUDIES JAN A, BurGeER, MD, PHD+, SusAN O'BRIEN, MD1, NATHAN FOWLER, MD2, RANJANA

  2. Slide 2: Jan Burger, MD

    Jan Burger, MD RESEARCH FUNDING/PI: Pharmacyclics EMPLOYEE: N/A STOCKHOLDER: N/A CONSULTANT: Pharmacyclics SCIENTIFIC ADVISORY BOARD: Pharmacyclics

  3. Slide 3: PCI-32765: Novel Small Molecule Btk Inhibitor

    PCI-32765 Novel Small Molecule Btk Inhibitor ¢ Formsa specific and irreversible bond with cysteine-481 in Btk ¢ Potent Btk inhibition * IC. =0.5nM ¢ Orally available = * Once daily dosing results in 24-hr Owe sustained target inhibition

  4. Slide 4: Btk Regulates Multiple Cellular Processes in CLL

    Btk Regulates Multiple Cellular Processes in CLL Burger JA and Gandhi V, 6 T cells eee @ IL4, TNFa cos0# BCD1S4 —__ 9; 8 ccLa/4 y o Survival- and eh resistance pathways CXCL12, CXCL13 B cell receptor (BCR) signaling — PCI-32765 blocks BCR signals and induces apoptosis Chemokine-mediated CLL migratio

  5. Slide 5: Patients Included in Pooled Analysis (N=54)

    Patients Included in Pooled Analysis (N=54) Phase 1a (N=16) Phase 1b/2 (N=38) 1 Cycle = 28 days with 7 days rest 1 Cycle = 28 days Cohort Dose (mg/kg/day) 1 1.25 Cohort Dose (mg/day) R/R 420 8.3 12:5 N 0 2.5 3 Naive 420 3 1 2 2 3 5.0 4 5 1 Cycle = 35 days with no rest Cohort Dose cD1 8.3 mg/kg/day c

  6. Slide 6: Baseline Characteristics (N=54)

    Baseline Characteristics (N=54) fiedian age, years (range! 68 (40-84) CLL/ SLL, n (%) 47 (87)/7 (13) Rai stage (N=44) 0, n (%) 5 (11) I/II, n (%) 25 (57) III/IV, n (%) 14 (32) Median prior therapies, number (range) 3 (1-10)* Nucleoside analogue, n (%) 41/43 (95) Anti-CD20 agents, n (%) 41/43 (95) Be

  7. Slide 7: Objectives of Pooled Analysis

    Objectives of Pooled Analysis * Describe the characteristics of the antitumor effect of PCI-32765 in pts with CLL/SLL: - Reduction in lymphadenopathy/splenomegaly - Kinetics of change in absolute lymphocyte count (ALC) * Summarize the objective response and time on treatment to date * Summarize the

  8. Slide 8: % Change in LN Dimensions

    -60 = % Change in LN Dimensions -100 - a il SLL (n=7) @ CLL(n=32) | 34 out of 39 evaluable pt had a nodal response = 87%

  9. Slide 9: ALC versus LN Response in Phase 1a Pts (N=16)

    ALC versus LN Response in Phase 1a Pts (N=16) @ = =) a B a = 2 = = = oOo al < == =I 2 = 200 Time (Days)

  10. Slide 10: ALC versus LN Response: Continuous Dosing

    ALC versus LN Response: Continuous Dosing Absolute Lymphocyte Count > SS as i & DA pre-treatment ALC x 109/L 20 0 2 4 6 8 10 12 14 16 18 Weeks 2 months on treatmen

  11. Slide 11: Response Rate (%) Evaluable Patients

    Response Rate (%) 60 20 32 evaluable patients 53% 25% | 0% CR PR Nodal Response (n=8) | wLymphocytosis (n=17) 2 months F/U (Phase 1b/2) Response in Evaluable Patients 13 evaluable patients 62% 15% 8% m | CR PR Nodal Response (n=1) (n=8) wLymphocytosis (n=2) 8 months F/U (Phase 1a)

  12. Slide 12: Time on Study (N=54)

    Time on Study (N=54) 0 eos C—SS========_— @ On Study (n=43) x —<< =. E-__SSSSSSS== SSS oc EeE== 4 Non-PD D/C (n=7) 8 —— —————— — i PD (n=4) ne = 4 — © a a © a = = a —————=__"' = . T 0 2 4 6 8 10 12

  13. Slide 13: % of Patients: All Adverse Events

    % of Patients All Adverse Events (2 10% Incidence) 100 80 - “1% Grade 3 60 @ % Grade 4 40 20 - o+—=_, _—_ aes ——__, cs @ 2 0 G 7S g RS es & ££ SF #F SF FS S a o* Rs) < Ss ye Ro

  14. Slide 14: % of Patients: All Adverse Events

    % of Patients All Adverse Events (2 10% Incidence) 100 “1% Grade 80 - @ % Grade 2 “1% Grade 3 60 - @ % Grade 4 40 ° 8 i c ‘amt (x ~~ > | | 14

  15. Slide 15: Overview of Grade Laboratory AEs

    Overview of Grade 23 Laboratory AEs ¢ Norenal or hepatic AEs reported ¢ No evidence of cumulative toxicity in pts with > 6 months follow up 100 > m™ % Grade 3 80 - m % Grade 4 % of Patients

  16. Slide 16: Conclusions

    Conclusions PCI-32765, an oral Btk inhibitor, is active and well tolerated in patients with CLL/SLL Rapid lymph node responses are associated with a transient lymphocytosis, indicating a unique phenomena of BCR-targeted therapy The lack of drug-related myelosuppression or cumulative toxicity support

  17. Slide 17: Acknowledgements

    ACKNOWLEDGEMENTS CLINICAL & LABORATORY SITE PERSONNEL * MDAnderson Cancer Center, Houston, TX Justin Cummings, Clayton Dreyer, Talia LaPushin, Manolo Pasia Diana Rodriguez, Shana White * Dept. of Medicine/Oncology, Stanford University, Stanford, CA Nini Estevez ,Sipra Choudhury ,, Dina Chinichian ,

  18. Slide 18: Back up Slides

    Back up Slides

  19. Slide 19: Frequency of Adverse Events (N=54)

    Frequency of Adverse Events (N=54) n(%) Any AE 50 (93) Grade > 3 AE 20 (37) Any Related AE 42 (78) Related Grade 2 3 AE 9 (17) Any SAEs 14 (26) Related SAEs** 6 (11) Deaths* 2 (4) *All deaths occurred in the setting of documented disease progression and determined not study related by investigator.

  20. Slide 20: Median Follow-up

    Median Follow-up (range) CLL SLL Best response CR PR LN/spleen PR w/ lymphocytosis SD PD Non-evaluable/TETE Phase 1a (n=16) 8.3 mos (0.5-11.7) a1 5 Phase Ib/2 (n=38) RR 420 Naive 1.8 mos 1.8 mos (0.7-3.7) (1.2-1.9) 26 al

Pharmacyclics — Conference Presentation (December 2010) on 6ix